We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.14B
AUM Growth
+$264M
Cap. Flow
+$499M
Cap. Flow %
15.9%
Top 10 Hldgs %
65.37%
Holding
91
New
20
Increased
10
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$159M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$94.1M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$83.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$61.6M
5
TSVT
2seventy bio
TSVT
+$59.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82.1M
2
STTK icon
Shattuck Labs
STTK
+$75.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$25.2M
4
NRIX icon
Nurix Therapeutics
NRIX
+$24.8M
5
BLUE
bluebird bio
BLUE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Financials 0.62%
3 Miscellaneous 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$557M 17.76%
11,284,280
– –
ANAB icon
2
AnaptysBio
ANAB
$1.67B
$261M 8.33%
7,521,024
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.72B
$224M 7.12%
5,523,358
+400,999
+8% +$15.6M
XNCR icon
4
Xencor
XNCR
$1.94B
$197M 6.27%
4,906,106
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$191M 6.08%
+4,033,882
New +$159M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$187M 5.97%
3,951,566
– –
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$123M 3.91%
2,224,403
+665,654
+43% +$34.7M
NUVB icon
8
Nuvation Bio
NUVB
$2.34B
$118M 3.76%
13,896,543
+185,026
+1% +$1.7M
ALEC icon
9
Alector
ALEC
$261M
$103M 3.29%
4,994,970
– –
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.34B
$90.3M 2.88%
2,639,706
+1,195,906
+83% +$37.8M
CRSP icon
11
CRISPR Therapeutics
CRSP
$5.58B
$81.7M 2.6%
+1,077,483
New +$94.1M
GRTS
12
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$77.3M 2.46%
6,012,232
+451,484
+8% +$5M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$5.02B
$71.4M 2.28%
+3,060,593
New +$61.6M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$65.6M 2.09%
2,759,505
– –
ITOS
15
DELISTED
iTeos Therapeutics
ITOS
$60.7M 1.93%
1,303,157
– –
RLAY icon
16
Relay Therapeutics
RLAY
$4.11B
$54.6M 1.74%
1,779,084
+393,808
+28% +$12.4M
KURA icon
17
Kura Oncology
KURA
$1.13B
$52.1M 1.66%
3,724,437
– –
ORIC icon
18
Oric Pharmaceuticals
ORIC
$1.37B
$51M 1.63%
3,468,944
– –
TSVT
19
DELISTED
2seventy bio
TSVT
$49.1M 1.57%
+1,917,063
New +$59.8M
AVIR icon
20
Atea Pharmaceuticals
AVIR
$430M
$48.1M 1.53%
+5,376,134
New +$83.8M
DSGN icon
21
Design Therapeutics
DSGN
$946M
$46.1M 1.47%
2,152,997
+289,899
+16% +$4.98M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$40M 1.28%
+940,636
New +$39.4M
JANX icon
23
Janux Therapeutics
JANX
$1.1B
$27.9M 0.89%
1,411,975
– –
PRDS
24
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$26.1M 0.83%
1,597,139
+1,226,125
+330% +$14.3M
VTYX
25
DELISTED
Ventyx Biosciences
VTYX
$25.8M 0.82%
+1,300,000
New +$24.6M
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2021 Portfolio in Review

As of Q4 2021, EcoR1 Capital held 91 positions worth $3.14B, up 9.2% from $2.87B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $499M of net new capital in Q4 2021, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Nurix Therapeutics, an estimated $24.8M trimmed.

  • EcoR1 Capital's largest Q4 2021 buy was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.
  • EcoR1 Capital added most to Protagonist Therapeutics in Q4 2021, an estimated $37.8M increase.
  • EcoR1 Capital's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $24.8M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2021, selling an estimated $82.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $3.14B portfolio in Q4 2021.
  • EcoR1 Capital opened 20 new positions and closed 15 in Q4 2021.
  • EcoR1 Capital's portfolio value rose 9.2% quarter-over-quarter to $3.14B.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.